Ian is the editor and a director of Proactive Investors. He oversees all editorial output and is also heavily involved with business development. He moved to Proactive from the Daily Mail, where he was City News Editor and Investment Editor and brings with him a wealth of experience in business and finance. At the Mail he directed the coverage of some of the biggest stories ever to emerge from the City as the credit crunch and banking crisis felled some of the nation's best known financial institutions. In his 20 years as a business reporter and editor Ian has worked for Dow Jones, writing stories for the international news wire and the Wall Street Journal. He also led the London company coverage for AFX News, now part of Reuters.
Depending on the read-out from current study, it may opt to submit the results from just one phase III trial in Europe. But at this stage it is only considering this option
The US weight management market alone is worth an estimated US$72bn
This, the firm said, would require building on the work carried out by the University Medical Centre Hamburg-Eppendorf
Investors were also told data from the trial is currently being collated for examination by independent experts, with Dr Mark Linch appointed as principal investigator
The US drug developer used the UK company's London facility and its specially designed trial protocol
The Food & Drug Administration gave approval for GSK’s Nucala to be given using an auto-injector or a pre-filled safety syringe
The drug developer is assessing the best route forward for its lead drug, a treatment for the autoimmune disease, Lupus
After a string of deals for its health products, including one earlier this week, the company said it had inked an exclusive agreement in Poland
Two companies, three wells
Drilling down into the world of E&P as we keep tabs of on the gushers and dusters
A look at some early analyst views in the City
The bookmakers have been put under the microscope, while Shell has been downgraded.